BioSpace News Archive

Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of an aggregate of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the

Foundation Grant Builds on Earlier Donation from Air Products China to Support Local Relief Efforts

Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the appointment of Julie Speed to the position of Chief Commercial Officer.

The American College of Rheumatology published the 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

CHAMPS Oncology, an industry leader in cancer registry operations, launched an online education session “2020 Cancer Program Insights - Optimal Resources for Cancer Care” based on the new Commission on Cancer standards.

Frontage Holdings Corporation, a contract research organization providing integrated, science-driven, product development services, is pleased to announce the expansion of its bioanalytical laboratories in Exton, PA, through its wholly-owned subsidiary, Frontage Laboratories, Inc.

The Canada Health Act provides the critical foundation for the Canadian health care system—a system that is a source of pride for Canadians.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ Coronavirus COVID-19 Test has obtained regulatory clearance to be sold as an in vitro diagnostic (“IVD”) for the diagnosis of SARS-CoV-2 (COVID-19)

Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has appointed Kamil Ali-Jackson, Esq. to its Board of Directors. Ms. Ali-Jackson will be a member of the Board’s audit committee. “We are very pleased to welcome Kamil to the Board of Directors and look forward to her insights a